Approval · Notice of Compliance 9063 · 2007
NEXIUM: Notice of Compliance 9063
Issued October 1, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9063
- Date
- October 1, 2007
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New formulation and new pediatric indication for use in pediatric patients 1-11 years
- Therapeutic class
- H+, k+-atpase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEXIUM | 02300524 | Marketed |
Medicinal ingredients
- ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 10 MG per PCK